Patients with chronic spontaneous urticaria improved early, with benefits lasting through the 52-week follow-up for those who ...

Every year, on October 1st, is World Urticaria Day, a day dedicated to raising awareness about urticaria, commonly known as ...

Goldman Sachs initiates Celldex Therapeutics 9CDLX) at neutral, citing concerns about market opportunity and lack of near-term catalysts. Read more here.

My battle with fibromyalgia, a chronic pain condition, began when I was in my second year at Nanyang Technological University ...

Chronic inflammation refers to a prolonged inflammatory response that involves a progressive change in the type of cells present at the site of inflammation. It is characterized by the ...

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study ...

(RTTNews) - Celldex Therapeutics, Inc. (CLDX), Wednesday announced results from phase 2 study of barzolvolimab for treatment of chronic spontaneous urticaria, an immune-related condition. At the end ...

Celldex Therapeutics shares declined after the company reported 52-week results for a Phase 2 study of barzolvolimab in chronic spontaneous urticaria, an immune-related condition. The stock was 19% ...

Celldex Therapeutics reported that its medicine for a condition that causes chronic hives reduced hive activity and, notably, ...

Celldex Therapeutics has unveiled 52-week results from a mid-stage study of its anti-KIT drug in chronic hives, raising ...

(150 mg Q4W) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust improvement across ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...